AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol (May 23, 2007). doi:10.1152/ajpregu.00807.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/R707    most recent
00807.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitzgerald, S. M.
Right arrow Articles by Evans, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitzgerald, S. M.
Right arrow Articles by Evans, R. G.
Submitted on November 16, 2006
Accepted on May 15, 2007

Endothelial dysfunction and arterial pressure regulation during early diabetes in mice: roles for nitric oxide and endothelium-derived hyperpolarizing factor

Sharyn Margaret Fitzgerald1, Barbara K. Kemp-Harper2, Helena C Parkington3, Geoffrey A. Head4, and Roger G. Evans5*

1 Population Health Research Unit, Baker Heart Research Institute, Melbourne, Victoria, Australia
2 Pharmacology, Monash University, Melbourne, Victoria, Australia
3 Physiology, Monash University, Melbourne, Victoria, Australia
4 Neuropharmacology Laboratory, Baker Medical Research Institute, Melbourne, Victoria, Australia
5 Physiology, Monash University, Clayton, Victoria, Australia

* To whom correspondence should be addressed. E-mail: roger.evans{at}med.monash.edu.au.

We determined whether nitric oxide (NO) counters the development of hypertension at the onset of diabetes in mice, whether this is dependent on endothelial NO synthase (eNOS) and whether non-NO endothelium-dependent vasodilator mechanisms are altered in diabetes in mice. Male mice were instrumented for chronic measurement of mean arterial pressure (MAP). In wild-type mice, MAP was greater after 5 weeks of N{omega}-nitro-L-arginine methyl ester (L-NAME, 100 mg·kg-1·day-1 in drinking water; 97±3 mmHg) than after vehicle treatment (88±3 mmHg). MAP was also elevated in eNOS null mice (113±4 mmHg). Seven days after streptozotocin treatment (200 mg/kg, iv) MAP was further increased in L-NAME-treated mice (108±5 mmHg), but not in vehicle treated mice (88±3 mmHg) or eNOS null mice (104±3 mmHg). In wild-type mice, maximal vasorelaxation of mesenteric arteries to acetylcholine was not altered by chronic L-NAME or induction of diabetes, but was reduced by 42±6% in L-NAME-treated diabetic mice. Furthermore, the relative roles of NO and endothelium-derived hyperpolarizing factor (EDHF) in acetylcholine-induced vasorelaxation were altered; the EDHF component was enhanced by L-NAME and blunted by diabetes. These data suggest that NO protects against the development of hypertension during early stage diabetes in mice, even in the absence of eNOS. Furthermore, in mesenteric arteries diabetes is associated with reduced EDHF function, with an apparent compensatory increase in NO function. Thus, prior inhibition of NOS results in endothelial dysfunction in early diabetes, since the diabetes-induced reduction in EDHF function cannot be compensated by increases in NO production.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.